{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:29:25Z","timestamp":1776788965526,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-23-20141"],"award-info":[{"award-number":["22-23-20141"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bmcl.2023.129283","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T11:41:11Z","timestamp":1681213271000},"page":"129283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["3-Arylidene-2-oxindoles as GSK3\u03b2 inhibitors and anti-thrombotic agents"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-3324","authenticated-orcid":false,"given":"Denis","family":"Babkov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Bezsonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2249-020X","authenticated-orcid":false,"given":"Viktor","family":"Sirotenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-2460","authenticated-orcid":false,"given":"Elias","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-943X","authenticated-orcid":false,"given":"Vladlen","family":"Klochkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-5944","authenticated-orcid":false,"given":"Sergey","family":"Sosonyuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-3694","authenticated-orcid":false,"given":"Natalia","family":"Lozinskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Spasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129283_b0005","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.bmcl.2023.129283_b0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0119-2018","article-title":"Cancer-associated thrombosis: the when, how and why","volume":"28","author":"Fernandes","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.bmcl.2023.129283_b0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","article-title":"The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications","volume":"127","author":"McFadyen","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.bmcl.2023.129283_b0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11239-019-01878-x","article-title":"Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism","volume":"48","author":"Giustozzi","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.bmcl.2023.129283_b0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7150\/ijbs.18485","article-title":"The myosin II inhibitor, blebbistatin, ameliorates fecl3-induced arterial thrombosis via the GSK3\u03b2-NF-\u03baB pathway","volume":"13","author":"Zhang","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.bmcl.2023.129283_b0030","unstructured":"Yin Z, Xu H jiang, Yao X li, et al. Ambient Fine Particles (PM 2 . 5) Attenuate Collagen-Induced Platelet Activation Through Interference of the PLC c 2 \/ Akt \/ GSK3 b Signaling Pathway. 2018;(August). 10.1002\/tox.22257."},{"key":"10.1016\/j.bmcl.2023.129283_b0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0014-5793(03)01015-9","article-title":"Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? 1","volume":"553","author":"Barry","year":"2003","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmcl.2023.129283_b0040","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood-2007-09-111518","article-title":"GSK3beta is a negative regulator of platelet function and thrombosis","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2023.129283_b0045","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1074\/jbc.M112.429936","article-title":"Dual regulation of glycogen synthase kinase 3 (GSK3)\u03b1\/\u03b2 by protein kinase C (PKC)\u03b1 and Akt promotes thrombin-mediated integrin \u03b1IIb\u03b23 activation and granule secretion in platelets","volume":"288","author":"Moore","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0050","doi-asserted-by":"crossref","unstructured":"Davidson DC, Spinelli SL, Phipps R. Antiplatelet Activity of Valproic Acid Contributes to Decreased Soluble CD40 Ligand Production in HIV Type 1-Infected Individuals. 2011;(January). 10.4049\/jimmunol.1001911.","DOI":"10.4049\/jimmunol.1001911"},{"key":"10.1016\/j.bmcl.2023.129283_b0055","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A Phase II Trial of tideglusib in Alzheimer\u2019s Disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bmcl.2023.129283_b0060","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3109\/10428194.2015.1122781","article-title":"An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia","volume":"57","author":"Rizzieri","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bmcl.2023.129283_b0065","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10637-015-0278-7","article-title":"A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin","volume":"33","author":"Gray","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmcl.2023.129283_b0070","article-title":"9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma","volume":"1","author":"Ugolkov","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bmcl.2023.129283_b0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1074\/jbc.M002466200","article-title":"Indirubins inhibit glycogen synthase kinase-3\u03b2 and CDK5\/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer\u2019s disease. A property common to most cyclin-dependent kinase inhibitors?","volume":"276","author":"Leclerc","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0080","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.bmc.2019.03.028","article-title":"Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3\u03b2 inhibitors","volume":"27","author":"Lozinskaya","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bioorg.2015.05.009","article-title":"Structure-based design of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3\u03b2 inhibitors to activate Wnt\/\u03b2-catenin pathway","volume":"61","author":"Yue","year":"2015","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0090","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ejmech.2007.06.016","article-title":"Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies","volume":"43","author":"Patel","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0095","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1021\/acs.jmedchem.8b00713","article-title":"Mathematical and structural characterization of strong nonadditive structure-activity relationship caused by protein conformational changes","volume":"61","author":"Gomez","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0100","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1021\/jm801070q","article-title":"Assessment of additive\/nonadditive effects in structure\u2212activity relationships: implications for iterative drug design","volume":"51","author":"Patel","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129283_b0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000214122","article-title":"Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors","volume":"5","author":"Seuter","year":"1976","journal-title":"Pathophysiol Haemos Thromb."},{"key":"10.1016\/j.bmcl.2023.129283_b0110","doi-asserted-by":"crossref","first-page":"10656","DOI":"10.3390\/ijms221910656","article-title":"Opposing roles of GSK3\u03b1 and GSK3\u03b2 phosphorylation in platelet function and thrombosis","volume":"22","author":"Moore","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.bmcl.2023.129283_b0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0049-3848(87)90130-7","article-title":"Two phasic generation of thromboxane A2 by the action of collagen on rat platelets","volume":"46","author":"Hanasaki","year":"1987","journal-title":"Thromb Res"},{"key":"10.1016\/j.bmcl.2023.129283_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128449","article-title":"Towards multi-target antidiabetic agents: In vitro and in vivo evaluation of 3,5-disubstituted indolin-2-one derivatives as novel \u03b1-glucosidase inhibitors","volume":"55","author":"Klochkov","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129283_b0125","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3390\/molecules28031174","article-title":"3-Arylidene-2-oxindoles as potent NRH: quinone oxidoreductase 2 inhibitors","volume":"28","author":"Lozinskaya","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bmcl.2023.129283_b0130","doi-asserted-by":"crossref","first-page":"222","DOI":"10.19163\/2307-9266-2021-9-3-222-234","article-title":"Synthesis, antiaggregation and antitrombotic activities of new derivatives of hydroxybenzoic acids with tauric fragment","volume":"9","author":"Brel","year":"2021","journal-title":"Pharm Pharmacol"},{"key":"10.1016\/j.bmcl.2023.129283_b0135","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/ph15050537","article-title":"Discovery of nitro-azolo[1,5-a]pyrimidines with anti-inflammatory and protective activity against LPS-induced acute lung injury","volume":"15","author":"Spasov","year":"2022","journal-title":"Pharmaceuticals"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23001610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23001610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:47:59Z","timestamp":1760773679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23001610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"alternative-id":["S0960894X23001610"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129283","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-Arylidene-2-oxindoles as GSK3\u03b2 inhibitors and anti-thrombotic agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129283"}}